aTyr Pharma (ATYR) to Announce Earnings on Thursday

aTyr Pharma (NASDAQ:ATYR) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. On average, analysts expect aTyr Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

aTyr Pharma Stock Performance

ATYR stock opened at $0.49 on Tuesday. The company has a market cap of $48.24 million, a P/E ratio of -0.67 and a beta of 0.54. aTyr Pharma has a fifty-two week low of $0.40 and a fifty-two week high of $6.50. The stock’s 50 day simple moving average is $0.51 and its 200 day simple moving average is $0.71.

Insider Buying and Selling at aTyr Pharma

In related news, Director Paul Schimmel acquired 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were bought at an average cost of $0.50 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the director owned 779,143 shares in the company, valued at approximately $389,571.50. This trade represents a 14.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 5.75% of the company’s stock.

Institutional Investors Weigh In On aTyr Pharma

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of aTyr Pharma by 21.0% during the 3rd quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock valued at $4,060,000 after purchasing an additional 975,887 shares during the last quarter. UBS Group AG lifted its position in aTyr Pharma by 158.1% in the 3rd quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock worth $3,249,000 after buying an additional 2,760,238 shares during the last quarter. Octagon Capital Advisors LP grew its position in aTyr Pharma by 7.5% during the second quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company’s stock valued at $19,367,000 after acquiring an additional 268,000 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of aTyr Pharma by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company’s stock worth $1,789,000 after acquiring an additional 105,514 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of aTyr Pharma by 22.0% in the 3rd quarter. Millennium Management LLC now owns 1,890,921 shares of the company’s stock worth $1,364,000 after acquiring an additional 340,721 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

ATYR has been the topic of several research reports. Wall Street Zen upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a report on Sunday, July 12th. Weiss Ratings downgraded shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Finally, Freedom Capital raised aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $17.00.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.